- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Lessons From The Obamacare Data Dump
This week the Department of Health and Human Services released a ton of information about how insurance sold in 36 states under the Affordable Care Act will work.
This week the Department of Health and Human Services released a ton of information about how insurance sold in 36 states under the Affordable Care Act will work. Most of it came in the form of data showing the number of carriers and their premium prices in hundreds of regions.
Until now we've seen information on subsidized policies to be sold through online marketplaces released in trickles by states that are creating their own online portals.
The federal data covers states that dumped all or part of the work of building the marketplaces on the feds. It’s the biggest chunk of information so far available, even though many critical pieces — the identity of the insurers, the structure of the benefits, the networks of the hospitals and doctors — won't be known until next week. That's when the online portals in every state are scheduled to start selling subsidized insurance made available by the ACA to those who aren't otherwise covered.
The Obama administration boasted that the premiums came out lower than expected. Opponents of the ACA countered that many people buying through the exchanges, especially younger, healthier consumers, may pay substantially more than what they pay now.
Read the full story here: http://bit.ly/192Pu1H
Source: Kaiser Health News
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
